EGFR and non-small cell lung carcinoma: Currently, a US-based multi-institutional study is assessing whether treatment escalation with the addition of platinum-doublet to osimertinib in patients with stage IV EGFRm NSCLC who have persistently detectable EGFR mutations through ctDNA analysis after 3 weeks of osimertinib will result in an improved duration of response to first-line therapy (NCT04410796).